# The Covid-19 Outpatient Symptom Montelukast Oximetry Trial

> **NCT04389411** · PHASE2,PHASE3 · UNKNOWN · sponsor: **McGill University** · enrollment: 250 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Montelukast 10mg

## Key facts

- **NCT ID:** NCT04389411
- **Lead sponsor:** McGill University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-01
- **Final completion:** 2025-02
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2022-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389411, "The Covid-19 Outpatient Symptom Montelukast Oximetry Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04389411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*